A wave of tools combining artificial intelligence with lab automation is reshaping how new medicines are found, according to a cluster of recent industry reports.
Two articles from News-Medical describe how AI is being paired with "organoids" — tiny, lab-grown 3D clusters of cells that mimic real human tissue — to build faster, more scalable drug-screening workflows. In a related interview, News-Medical's AZoLife Sciences spoke with Boyd Butler, a microscopy and high-content screening expert at Molecular Devices, about AI's growing role in high-content screening: the practice of using automated imaging to study how cells respond to candidate drugs. The discussion highlighted AI-driven 3D imaging and "phenotypic discovery," which looks at how cells visibly change rather than targeting a single known mechanism.
On the software side, MarkTechPost reports that NVIDIA has released an open-source BioNeMo Agent Toolkit. It converts biomolecular models — including OpenFold3, DiffDock and GenMol — into documented, callable "skills" that AI agents can use. According to MarkTechPost, each skill spells out a model's purpose, inputs, outputs and failure modes, so an AI agent can pick the right tool, run it, and interpret the results on its own.
Together, the reports point to a shift from researchers manually running individual experiments and models toward systems where AI helps choose, operate and read the results of complex biology tools at scale.
Why it matters: drug discovery is famously slow and expensive, and tools that let AI orchestrate lab work and analysis could shorten the path from idea to viable treatment.